The fourth new crown vaccine developed in China received clinical approval and clinical trials will start tomorrow
Surging News (www.thepaper.cn) learned on the evening of April 27 from Sinopharm Group China Biotechnology Co., Ltd. (hereinafter referred to as "China Bio") that China Bio-Beijing Biological Products Research Institute (hereinafter referred to as "Beijing Bio") developed Of the new crown inactivated vaccine was approved by the State Drug Administration for clinical trials.
The relevant person in charge of China's biology told Peng Mei News that the new crown inactivated vaccine that has just received clinical approval will officially start clinical trials in Henan on April 28.
The new inactivated coronavirus vaccine developed this time. Photo courtesy of China Bio
It is understood that this is also the second new crown inactivated vaccine approved by China Biotechnology. In addition to the adenovirus vector recombinant new coronavirus vaccine developed by the academician Chen Wei team of the Academy of Military Medical Sciences and the new inactivated vaccine developed by Beijing Kexing Zhongwei Biotechnology, four new crown vaccines have been approved for clinical trials in China.
According to the news released by China Bio, the approved new inactivated vaccine was jointly developed by China Bio Beijing Institute of Biological Products and China National Center for Disease Control and Prevention.
In addition, China Bio has established a new crown workshop construction team, and has completed the construction of a new crown virus vaccine production workshop in Beijing. After mass production, the annual production capacity will reach 100 million doses, and it has the production conditions to meet large-scale emergency use and routine vaccination.
On April 12, the New Crown Inactivated Vaccine, a collaborative research project between the Wuhan Institute of Biological Products of China and the Wuhan Institute of Virology, Chinese Academy of Sciences, was the first to obtain the first clinical trial approval in the world. The Clinical Research Center of the Prevention and Control Center took the lead and was undertaken by the Wuzhi County Center for Disease Control and Prevention, Jiaozuo City, Henan Province, and entered the phase II clinical trial stage on April 24.
Yang Xiaoming, vice president of the China Pharmaceutical Biotechnology Association and chief scientist of the national "863" plan vaccine project, explained that the reason why multiple teams and multiple technical routes are arranged in parallel is to develop a vaccine that can fight the epidemic earlier. As far as the technical route of inactivated vaccines is concerned, the R & D capabilities of these two teams are very strong. Both have mature experience in emergency SARS vaccine development in 2003. The double insurance is to ensure the foolproof development and production of vaccines.
Reporter Hu Danping Wu Yurong Lu Xinwen